Marizyme Inc MRZM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRZM is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.10
- Day Range
- $0.10–0.10
- 52-Week Range
- $0.05–0.41
- Bid/Ask
- $0.00 / $0.13
- Market Cap
- $4.43 Mil
- Volume/Avg
- 2,180 / 8,078
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.85
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
- Website
- https://www.marizyme.com
Valuation
|
Metric
|
MRZM
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 6.85 |
Price/Cash Flow | — |
Price/Earnings
MRZM
Financial Strength
|
Metric
|
MRZM
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.03 |
Interest Coverage | −2.34 |
Quick Ratio
MRZM
Profitability
|
Metric
|
MRZM
|
|---|---|
Return on Assets (Normalized) | −93.97% |
Return on Equity (Normalized) | −342.23% |
Return on Invested Capital (Normalized) | −74.68% |
Return on Assets
MRZM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hggftvzzg | Bxmc | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lzbkgfnq | Dxmlnn | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mqjjrbh | Hqcnh | $97.8 Bil | |
MRNA
| Moderna Inc | Hqclzbdfv | Rnbz | $41.3 Bil | |
ARGX
| argenx SE ADR | Xscxdps | Wzyj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Lkkxqjlt | Yxks | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Phkpbsz | Wxpwkp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pnxhhqjt | Hkwvt | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bbrsksgjhw | Knjhcpb | $12.5 Bil | |
INCY
| Incyte Corp | Nfbzcbls | Rhxdz | $11.6 Bil |